Ultime notizie per Society Pass (NASDAQ:SOPA) Azioni

Society Pass

Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.

Society Pass Inc

Acuity Inc. (NYSE: AYI) reported <a href="https://www.benzinga.com/pressreleases/25/06/g46110763/acuity-reports-fiscal-2025-third-quarter-results" target="_blank" rel="noreferrer noopener">fiscal third-quarter 2025</a> results on Thursday. The company reported quarterly net sales growth of 21.7% year-over-year to $1.18 billion, topping the analyst consensus estimate of $1.15 billion. 
It clocked an adjusted EPS of $5.12, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $4.43.
Breaking down Acuity&#8217;s sales by segment shows strong growth in Acuity Intelligent Spaces (AIS), which surged to $264.1 million, a remarkable 248.9% increase from the previous year. Meanwhile, Acuity Brands Lighting (ABL) contributed $923.2 million, marking a 2.7% year-over-year rise.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44626729/acuity-brands-q2-earnings-tops-eps-estimates-intelligent-spaces-sales-surge-over-150-grows-margins-and-ebitda-despite-cash-flow-decline-and-sales-miss" rel="noreferrer noopener">Acuity Brands Q2 Earnings: Tops EPS Estimates, Intelligent Spaces Sales Surge Over 150%, Grows Margins, EBITDA Despite Cash Flow Decline And Sales Miss</a>
Operating margin declined by 310 bps to 11.9%, while profit declined by 3.8%. During the quarter, the company accelerated productivity actions in its ABL segment, which resulted in $29.7 million of special charges.&nbsp;
The consolidated adjusted operating margin grew by 150 bps to 18.8%. ABL&#8217;s adjusted operating margin improved by 80 bps to 18.8%. AIS&#8217; margin increased by 70 bps to 23.6%.
The company generated $207.3 million in operating cash flow for the first six months of fiscal year 2025, compared to $152.5 million a year ago. Free cash flow was $192.3 million.
Acuity held cash and equivalents of $371.8 million as of May 31, 2025, compared to $845.8 million as of August 31, 2024.
Adjusted EBITDA was $236.3 million, up from $180.0 million a year ago.&nbsp;The margin expanded by 140 bps to 20.0%.
Price Action: AYI stock closed higher by 1.35% at $291.38 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46100456/tesla-robotaxi-scaling-growth-will-be-slow-in-near-term-goldman-sachs" target="_blank" rel="noreferrer noopener">Tesla Robotaxi Scaling Growth Will Be Slow In Near Term: Goldman Sachs</a></li>
</ul>
Photo via Shutterstock

Earnings

News

Acuity's Smart Play Pays Off As Intelligent Spaces Revenue Skyrockets

Management

ADUR

Aduro Clean Technologies Appoints David Weizenbach As COO, Effective July 1st 2025

Jefferies analyst Janardan Menon downgrades ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) from Buy to Hold.

Downgrades

Analyst Ratings

ASML

Jefferies Downgrades ASML Holding to Hold

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and maintains $50 price target.

Price Target

Reiteration

IONS

HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $50 Price Target

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) CEO Satya Nadella believes that while AI is already accelerating scientific breakthroughs, the true game-changer will be when quantum computing is integrated into the mix.
What Happened: During a fireside chat with Gary Tan at Y Combinator's AI Startup School that was posted on YouTube on Wednesday, Nadella shared his vision for the future of AI, quantum computing and supercomputing.
He explained that AI, along with high-performance computing (HPC), has already made significant strides in fields like chemistry, physics, and material science. However, he believes that quantum computing will take these advancements to the next level.
See Also:&nbsp;<a href="https://www.benzinga.com/tech/25/04/45090992/mark-zuckerberg-warns-of-serious-disadvantage-as-chinas-data-center-blitz-could-let-deepseek-leapfrog-us-ai-labs" target="_blank" rel="noreferrer noopener">Mark Zuckerberg Warns Of ‘Serious Disadvantage' As China's Data-Center Blitz Could Let DeepSeek Leapfrog US AI Labs</a>
"If you want to understand the language of nature, which is simulation, I think the best way to do it is through a quantum computer because, after all, physics and nature are quantum," Nadella said. "AI is … an emulator of that simulator."
"What we are seeing is pretty good advances in using basically HPC+AI as a way to accelerate advances in Chemistry, in Physics, in Material Science and so quantum would be the next step in it. But we&#8217;re very excited about what AI+quantum and HPC in a loop can do," he added.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Satya Nadella: Microsoft&#039;s AI Bets, Hyperscaling, Quantum Computing Breakthroughs" width="500" height="281" src="https://www.youtube.com/embed/AUUZuzVHKdo?start=69&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Why It's Important: In February earlier this year, Microsoft debuted its first quantum chip, Majorana 1, powered by a breakthrough Topological Core architecture designed to support quantum computers capable of solving complex, real-world problems within a few years.
At the heart of this innovation is the topoconductor—a custom-built material that enables the creation and control of Majorana particles, which in turn produce more stable, scalable qubits, the foundational units of quantum computing.
Microsoft said this approach could ultimately pack one million qubits onto a chip small enough to fit in a hand, unlocking applications like breaking down microplastics and creating self-healing materials.
This announcement <a href="https://www.benzinga.com/tech/24/12/42397333/google-quantum-ais-new-willow-chip-can-do-in-minutes-that-supercomputers-would-take-10-septillion-years">came just months after</a> Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google introduced its Willow quantum chip.
Previously, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang said <a href="https://www.benzinga.com/markets/tech/25/06/45885805/nvidias-jensen-huang-sparks-quantum-stock-frenzy">quantum computers are nearing the point</a> where they can solve real-world problems beyond the reach of traditional computers.
Speaking at the GTC Paris developer conference, Huang reversed his earlier cautious stance, calling this "an inflection point" for the technology and predicting meaningful applications within a few years.
Benzinga's Edge Stock Rankings indicate a favorable trend for Microsoft across short, medium and long-term periods. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">More in-depth performance metrics can be found here</a>.
<figure class="wp-block-image aligncenter size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26060159/Screenshot-2025-06-26-at-12.41.13%E2%80%AFPM-1.png" alt="" class="wp-image-962969" /></a></figure>
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45396297/cathie-wood-dumps-palantir-as-stock-touches-peak-prices-bails-on-soaring-flying-taxi-maker-archer-aviation" target="_blank" rel="noreferrer noopener">Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Imagn

Tech

GOOG

GOOGL

MSFT

NVDA

AI Is Already Speeding Up Discoveries In Chemistry And Physics, But Satya Nadella Says The Real Breakthrough Will Come When We Add Quantum Computing To The Mix

MU: 7% &#x7C; <a href="https://www.benzinga.com/node/46103438">Micron shares are trading higher after the company reported better-than-expected Q3 EPS and sales and issued strong Q4 guidance above estimates.</a>
&nbsp;
CYN: 133% &#x7C; <a href="https://www.benzinga.com/node/46111889">Cyngn Partners with NVIDIA to Showcase Autonomous Industrial Vehicles at Automatica 2025</a>
&nbsp;
IRD: 37% &#x7C; <a href="https://www.benzinga.com/node/46111841">Viatris And Opus Genetics Say VEGA-3 Phase 3 Trial Meets Primary And Key Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity</a>

Movers

Trading Ideas

Market-Moving News for June 26th

Needham analyst Quinn Bolton maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and raises the price target from $120 to $150.

Needham Maintains Buy on Micron Technology, Raises Price Target to $150

~ Increasing revenue, combining scale, and realizing immediate synergies ~ ~ Creating a dominant force in high-growth mmWave and defense semiconductor markets ~ ~ Securing Nasdaq listing stability for Peraso shareholders ~
Mobix Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) ("Mobix") today announcedan unsolicited, non-binding proposal to acquire Peraso, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) ("Peraso") in a premium stock-for-stock transaction.
Under the proposed terms, Mobix will exchange newly issued MOBX common shares for each PRSO share at a 20% premium to Peraso's 30-day average closing share price through June 10, 2025.
Transaction Highlights &amp; Shareholder Benefits
<ul>
<li>Revenue Accretion &amp; Scale:
<ul>
<li>Peraso Q1 2025 revenue exceeded that for its entire 2024 fiscal year.</li>
<li>Peraso delivered approximately $1.5 million in 5G/mmWave revenues in Q1 2025, compared to an annual revenue of $1.3 million in 5G/mmWave revenues for fiscal year 2024. This significant increase in mmWave revenue reflects a strong 5G/mmWave semiconductor demand.</li>
<li>Mobix generated over $10.7 million in trailing-12-month revenue, posting an exceptional ~450% YoY growth.</li>
<li>The combined company could command approximately $20 million in annual revenue, enhancing scale and accelerating profitability.</li>
</ul>
</li>
<li>Margin Enhancement &amp; Operational Leverage:
<ul>
<li>Based on publicly available data, Peraso has reported gross margins of approximately 57% in 2024, which closely aligns with Mobix's historical performance.</li>
<li>Scale-driven synergies in sales, production, and procurement are expected to improve overall profitability.</li>
</ul>
</li>
<li>Product &amp; Market Synergies:
<ul>
<li>Peraso's market-leading 5G/mmWave chipsets and software complement Mobix's established platforms in defense, aerospace, AI datacenter, and 5G markets.</li>
<li>Integration of Peraso's IP will unlock cross-selling opportunities across Mobix's defense, satellite, and datacenter customer base, accelerating time-to-market and widening margins.</li>
</ul>
</li>
<li>Immediate Value to Peraso Shareholders:
<ul>
<li>Apremium offer at +20% above 30-day average price, coupled with exposure to Mobix's rapidly growing revenue base and broadened sector diversification.</li>
<li>Enhanced access to capital markets and Nasdaq-listed equity, enabling stronger liquidity and investor reach compared to standalone execution.</li>
<li>Continued upside potential through synergy realization, efficiency gains, and joint innovation in high-growth semiconductor verticals.</li>
</ul>
</li>
<li>Market Cap and Listing Risk:
<ul>
<li>As of June 11, 2025, Peraso's market capitalization is approximately $5.9 million, reflecting a closing share price of $1.15 and roughly 5.1 million shares outstanding.</li>
<li>According to Peraso's recent SEC filings, the company must raise its market value to at least $35 million by November 2025 to maintain Nasdaq compliance. Mobix believes its proposal provides a viable path to meeting that requirement through strategic scale and access to capital markets</li>
<li>Mobix's proposal not only offers a 20% premium but offers a strategic path forward that preserves Nasdaq listing, enhances scale, and delivers immediate value to Peraso shareholders.</li>
</ul>
</li>
</ul>
Mobix Labs has submitted this non-binding proposal directly to the Peraso Board of Directors on June 12, 2025, and is issuing a press release and filing a Form 8-K to ensure full transparency, as Peraso has not disclosed Mobix Labs' unsolicited offer as of this date. Should Peraso's board decline to engage, Mobix Labs is prepared to consider alternative avenues to present its proposal directly to shareholders, consistent with regulatory requirements.

MOBX

PRSO

Mobix Labs Announces Unsolicited, Non-Binding Proposal To Acquire Peraso In Premium Stock-For-Stock Transaction

Telsey Advisory Group analyst Dana Telsey maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Outperform and maintains $520 price target.

ULTA

Telsey Advisory Group Maintains Outperform on Ulta Beauty, Maintains $520 Price Target

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) with a Buy and maintains $5 price target.

HOTH

D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target

Bernstein analysts have raised their price target for Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) to $510, citing accelerating growth in the company's derivatives business and <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">non-trading revenue streams</a>.
The updated price target marks a significant jump from the previous $310 target, reflecting Bernstein's increased confidence in Coinbase's evolving position as a leading crypto financial services platform.
Bernstein now values Coinbase at a price-to-earnings multiple of 25x based on 2027E earnings, up from its previous estimate of 21x on 2026 earnings, aligning the crypto exchange's valuation with its fintech and broker peers.
The brokerage house highlighted several drivers behind the target upgrade, including faster-than-expected revenue growth in non-trading businesses such as staking, stablecoins, and the company&#8217;s Base blockchain. 
The report also pointed to Coinbase's growing derivatives volumes, particularly in perpetual futures, which have shown a substantial increase in recent quarters.
Bernstein's revised model now forecasts Coinbase's total revenue to reach approximately $14.1 billion by 2027, up from the earlier estimate of $12.4 billion. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46095358/can-ledgers-mev-max-vault-boost-your-eth-rewards-what-crypto-stakers-need-to-know">Can Ledger&#8217;s MEV Max Vault Boost Your ETH Rewards? What Crypto Stakers Need To Know</a>
The firm's adjusted earnings per share estimate for 2027 has been lifted to $20.38, reflecting higher operating leverage.
&#8220;Operating leverage drives net income growth for Coinbase,&#8221; the report noted, supporting the thesis for an increased valuation.
Despite regulatory headwinds in past years, Bernstein sees Coinbase's market leadership as strengthening, particularly after the withdrawal of enforcement actions by U.S. regulators. 
The report emphasized Coinbase's dominant role in the U.S. spot crypto trading market and its expanding institutional business.
The analysts further noted that Coinbase&#8217;s share of perpetual futures volume climbed from 2.4% to 4.0% between Q4 FY24 and Q1 FY25, while the ratio of perpetual futures to spot trading volumes on its platform grew from 0.2 to 1.9 over the same period.
Bernstein described Coinbase as the "Amazon of crypto financial services," underscoring the company's integrated offerings across trading, custody, financing and staking.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46093380/as-bing-goes-private-presearch-opens-censorship-resistant-search-api-for-developers">As Bing Goes Private, Presearch Opens Censorship-Resistant Search API For Developers</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

COIN

Coinbase Is The 'Amazon Of Crypto Services', Price Target Boosted To $510: Bernstein

PDYN

Mobilicom And Palladyne AI Unveil Bundled Cybersecurity And AI Autonomy Solution For Secure, Autonomous Operations In Drones And Robotics

XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRTX#NASDAQ">XRTX</a>, TSXV:<a class="ticker" href="https://www.benzinga.com/stock/XRTX#TSXV">XRTX</a>, Frankfurt: ANU))), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces a non-brokered private placement to raise up to USD $925,000 through the issuance of up to 1,267,123 common share units of the Company at a price of USD $0.73 per unit (the "Offering"). Each Unit will comprise one common share and one common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder, on exercise, to purchase one additional common share in the capital of the Company, at a price of USD $1.20 per Warrant until the close of business on the day which is 60 months from the Closing Date, provided, however, that if the closing price of the common shares on the Nasdaq is greater than USD $2.00 for 10 or more consecutive trading days, the Warrants will be accelerated and the Warrants will expire on the 30th business day following the date of such notice.

TSXV:XRTX

XRTX

XORTX Therapeutics Announces Non-Brokered Private Placement To Raise Up To $925K Through Issuance Of Up To 1.27M Common Share Units At $0.73/Unit

Needham analyst Bernie McTernan reiterates AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from Hold to Hold.

Needham Reiterates Hold on AppLovinto Hold

Rosenblatt analyst Kevin Cassidy maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and raises the price target from $172 to $200.

Rosenblatt Maintains Buy on Micron Technology, Raises Price Target to $200

CRISPR Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases today announced updates across its in vivo cardiovascular disease programs. These include new data for CTX310&#x2122;, targeting ANGPTL3, as well as continued progress on CTX320&#x2122;, targeting the LPA gene, and CTX340&#x2122;, targeting the AGT gene.
"CRISPR Therapeutics remains focused on executing against our strategic priorities and advancing our portfolio of innovative therapies," said&nbsp;Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of&nbsp;CRISPR Therapeutics. "The additional data from our ongoing Phase 1 clinical trial for CTX310 reinforces the potential of our platform to transform the treatment of serious cardiovascular diseases. We are progressing with our dose-finding study and expect to share complete data at a medical meeting in the second half of this year. For CTX320, we are continuing our dose-finding study and anticipate sharing data in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) treatment landscape."
CTX310, targeting ANGPTL3
<ul>
<li>CTX310 targets&nbsp;ANGPTL3, a gene that encodes for key protein involved in the regulation of low-density lipoprotein (LDL) and triglyceride (TG) levels – both of which are recognized risk factors for atherosclerotic heart disease (ASCVD). Loss-of-function mutations in ANGPTL3 are associated with significantly reduced levels of LDL and TGs, as well as reduced risk of ASCVD, without known adverse health effects. More than 40 million patients in the U.S. alone are affected by elevated LDL, severely elevated TG or both – representing a significant unmet need and a large addressable population. CTX310 is initially focused on high-risk patients with the greatest unmet medical need and limited effective treatment options.&nbsp;</li>
<li>CTX310 is in an ongoing Phase 1 first-in-human clinical trial targeting ANGPTL3 in four patient groups: homozygous familial hypercholesterolemia (HoFH), severe hypertriglyceridemia (sHTG), heterozygous familial hypercholesterolemia (HeFH), or mixed dyslipidemias (MDL). Eligible participants have levels of TG &gt;300 mg/dL and/or LDL-C &gt;100 mg/dL (or &gt;70 mg/dL for subjects with ASCVD). Both LDL and TG are validated surrogate endpoints accepted by regulatory agencies.</li>
<li>These new results build upon previously disclosed results from the first 10 patients across the first four cohorts (lean body weight-based doses of DL1 [0.1 mg/kg], DL2 [0.3 mg/kg], DL3 [0.6 mg/kg] and DL4 [0.8 mg/kg]) with at least 30 days of follow-up for each participant. As dose-range finding continues, data to date demonstrate peak reductions of up to 82% in TG and LDL reductions of up to 86% at DL4 without any clinically significant changes in liver enzymes and a safety and tolerability profile consistent with previous findings.</li>
<li>The Company anticipates presenting the complete Phase 1 data for CTX310 at a medical meeting in the second half of 2025.</li>
</ul>
CTX320&#x2122;, targeting LPA
<ul>
<li>CTX320 is in an ongoing Phase 1 clinical trial targeting the&nbsp;LPA&nbsp;gene in patients with elevated lipoprotein(a) [Lp(a)], a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events (MACE). Elevated Lp(a) levels affect up to 20% of the global population and remains unaddressed by current therapies.</li>
<li>The Phase 1 trial is enrolling patients and dose-finding is ongoing. An update is now expected in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) landscape.</li>
</ul>
CTX340, targeting angiotensinogen (AGT)
<ul>
<li>CRISPR Therapeutics is also advancing its preclinical in vivo cardiovascular program CTX340, targeting angiotensinogen (AGT) for the treatment of refractory hypertension. CTX340 is currently progressing through IND/CTA-enabling studies.</li>
</ul>

CRSP

CRISPR Therapeutics Reports Progress on Gene-Based Treatments for Cardiovascular Diseases with New Data on CTX310 and CTX320

SERV

Serve Robotics Expands Autonomous Delivery Service To Atlanta With Uber Eats, Shake Shack, And Local Favorites

Organizations require proactive PQC readiness strategies to safeguard assets, preserve customer trust, and uphold compliance mandates
F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>), the global leader in delivering and securing every app and API, is helping customers prepare for the foundational cybersecurity shift presented by quantum computing. New comprehensive post-quantum cryptography (PQC) readiness solutions are seamlessly integrated into the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.f5.com%2Fproducts%2Ff5-application-delivery-and-security-platform&amp;esheet=54282466&amp;newsitemid=20250626252498&amp;lan=en-US&amp;anchor=F5+Application+Delivery+and+Security+Platform&amp;index=1&amp;md5=067e6dbe9e6be9fe40df666102affb22">F5 Application Delivery and Security Platform</a>, equipping organizations with the tools they need to secure applications and APIs while maintaining high performance and scalability.

FFIV

F5 Launches PQC Readiness Solutions To Secure Apps And APIs

LTRX

Lantronix Secures Multi-Year Deal With Tier-1 US Wireless Operator To Digitally Monitor 50,000+ Backup Generators For Enhanced Network Reliability

<a href="https://www.globenewswire.com/Tracker?data=iu-BaN1J6h2DCCdb4JH88Dcdb-bOBYnLmQi2cHJDIttnRAghQgbfFgLzbR2I5gOSCyd1TrijwPxcuGY1SvZhNQ==">GXO Logistics, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>), the world's largest pure-play contract logistics provider, today announced the launch of <a href="https://www.globenewswire.com/Tracker?data=IOMI2bqN1zRScaDUVLy768OpQwv18SMwQgmxVD8G9xtNI4GcR57K8tdgQ-hxjuzeX911XoXdGzzpYiIinQkBcdDMt9XvihPOIWrnJd8-J50=">GXO IQ</a>, the first AI-powered intelligent platform built for the logistics industry by logistics experts. GXO IQ will help businesses navigate the complexity of today's global supply chains by deploying industry-leading AI capabilities that orchestrate more productive, more dynamic logistics operations.
"Today marks a milestone for GXO and a pivotal moment for the industry as we launch GXO IQ, the first-ever AI-powered, cloud native operating system developed specifically for logistics," said Nizar Trigui, Chief Technology Officer of GXO. "There are few environments more dynamic or complex than a modern warehouse. Thousands of micro decisions are made every day in every site. As throughput increases, experts need a system that thinks with them to effectively anticipate, manage and orchestrate operations intelligently. That's exactly why GXO IQ was built - to be the logistics operating system of the future."
Informed by over 20 years of operational data, GXO IQ leverages a suite of proprietary AI algorithms that intelligently orchestrate millions of complex, multi-step actions across inventory distribution and movement, order picking and packing, shipping, and staffing. GXO IQ was designed by logistics experts and leverages a best-in-class technology stack including Google Cloud's Vertex AI and Snowflake Cortex AI. The tool also leverages Google Cloud's API management product Apigee to give customers secure and seamless access to critical warehouse data.&nbsp;&nbsp;
GXO IQ is comprised of four layers that create a seamless, intelligent operating platform:
<ul>
<li>Data Fabric Layer: GXO IQ utilizes GXO's operational expertise from 20 years of deploying supply chain solutions for customers, along with inputs from thousands of frontline operators, and a data lake that utilizes billions of transactions from GXO operations. Every day, over 200 million signals are streamed and organized to form the data fabric of the platform that trains powerful AI algorithms on every aspect of logistics operations.</li>
<li>AI Orchestration Layer: The AI algorithms are continuously running in the background, predicting demand shifts, anticipating inventory risks, proactively initiating inventory movement, and identifying the ideal pick, pack, and ship process of each order - all in real-time.</li>
<li>End-to-End Execution Layer: The execution layer is comprised of a full suite of logistics management capabilities with marketplace integration and value-added micro-services, including order management, warehousing, returns, and transportation. Services are fully integrated into a cohesive end-to-end solution that can be customized to meet the evolving needs of each individual customer using the platform.</li>
<li>Experience Layer: A unique, persona-based interface with a native, interactive AI agent called ‘GIL' provides a single view to see what's important and help manage the entire process, from real-time order fulfilment status to exceptions management to inventory risk alerts. GIL offers interactive insights that identify opportunities, answers questions and translates complexities into executable recommendations.</li>
</ul>

GXO Logistics Launches GXO IQ, an AI-Powered Platform to Transform Global Supply Chains

Press Releases

Momentum Stocks: PNPN.V, REBN, SOPA, KAVL, ZONE – Announcements Driving Growth

Ascendiant Capital Markets: Society Pass Inc (Nasdaq: SOPA) 1Q 2025 Sees Growth Over the Next Year with 2 IPOs Providing Key Catalysts in 2025

KAVL

PNPNF

REBN

SOPA

TSXV:PNPN

ZONE

Antelope Enterprise Holdings Limited - Class A Ordinary Shares

Antelope Ent Hldgs

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

Fangdd Network Group Ltd. - Class A Ordinary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Comments

Society Pass

Notizie

Ultime notizie per Society Pass (NASDAQ:SOPA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO